Tarsus Pharmaceuticals

$29.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.65 (-2.13%) As of 4:21 PM UTC today

Why Robinhood?

You can buy or sell TARS and other stocks, options, and ETFs commission-free!

About TARS

Tarsus Pharmaceuticals, Inc. develops and manufactures drug treatments for Blepharitis. The company focuses on treatment of Blepharitis, which is a common ocular condition, characterized by inflammation of the eyelid, which can impact the anterior or posterior lid or both. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA. The listed name for TARS is Tarsus Pharmaceuticals, Inc. Common Stock.

CEO
Bobak Azamian
Employees
—
Headquarters
Irvine, California
Founded
2017
Market Cap
676.03M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
49.91K
High Today
$32.42
Low Today
$29.91
Open Price
$31.28
Volume
11.13K
52 Week High
$63.69
52 Week Low
$15.32

TARS Earnings

-$3.71
-$2.47
-$1.24
$0.00
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 16, Pre-Market

You May Also Like

EMRAF
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure